News

Sosei has previously entered into a licensing agreement with Mundipharma, under which Mundipharma were granted the right to commercialize AD 923 in Europe and other international markets, excluding

Latisse is said to be the first science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.

Perrigo is expecting to begin product shipments to retailers during the first quarter of 2009. The product will be marketed under store brand labels and is comparable to

In the Phase II clinical trial, mechanically ventilated intensive care patients, who are at particular high risk of acquiring severe and often life-threatening forms of Pseudomonas aeruginosa infections,

Ms Sofer was appointed in December 2005 to lead Yissum. She joined Yissum from the venture capital industry where she held a series of senior roles in Israel

The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. miRview meso differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the

iCAD said that it has received CE Mark approval to market and sell its customized solution with Agfa HealthCare’s computed radiography systems and units have been placed at

Potential trade names are still under review with the FDA. Following issuance of a trade name, Ferring Pharmaceuticals, USA is expected to immediately begin commercialization in the US. Previously, the

The option period ends on March 31, 2009. Terms of the option stipulate that the primary use of SemBioSys’s plant-produced insulin would be for Afresa, MannKind’s insulin, which